GLP-3/R 30mg
$125.00
Description
GLP-3/R is a next-generation triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. By activating three distinct hormonal pathways, GLP-3/R represents the most advanced metabolic peptide in current research—delivering unmatched appetite suppression, energy expenditure, and fat oxidation compared to single- or dual-agonist compounds.
Mechanism of Action:
- GLP-1 agonism → Enhances glucose-dependent insulin release, reduces gastric emptying, and suppresses appetite centrally.
- GIP agonism → Amplifies insulin secretion and improves lipid metabolism and adipocyte function.
- Glucagon agonism → Increases basal metabolic rate and fat oxidation while preserving lean tissue mass.
Together, these three pathways create a comprehensive metabolic response: reduced caloric intake combined with increased metabolic output.
Research Highlights:
Phase 2 clinical data (Eli Lilly, 2023) demonstrated average body-weight reductions exceeding 24% over 48 weeks—the largest reductions observed with any single metabolic peptide to date. Significant improvements were also noted in insulin sensitivity, triglyceride profiles, and hepatic steatosis markers.
References: PMID 37680170 | 37351205 | Nature Metab 2024
Potential Applications (for research use):
- Obesity and metabolic-syndrome models
- Non-alcoholic fatty-liver disease (NAFLD) research
- Insulin resistance and lipid-metabolism pathway studies
Stacking Callouts:
May be co-researched with AOD-9604 for enhanced lipolytic targeting, or with MOTS-C for mitochondrial energy optimization.
For laboratory and research use only. Not for human consumption.
